Reducing the risk of cardiovascular disease in older women

References

• Bittner V. Perspectives on dyslipidemia and coronary heart disease in women. J Am Coll Cardiol 2005; 46; 1628–350.
   PubMed Web of Science ®Google Scholar
• American Heart Association. Heart disease and stroke statistics: 2006 update. Available at: http://americanheart.org. Downloaded 05 December 2006.
   Google Scholar
• Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham study. Ann Intern Med 1978; 89(2): 157–61.
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83–90.
   PubMed Web of Science ®Google Scholar
• Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of the Framingham population. Am Heart J 1986; 111: 383–90.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein level: a meta-analysis of population based prospective studies. J Cardiovasc Risk 1996; 3: 213–9.
   PubMedGoogle Scholar
• Lerner DJ, Kannel WB. Patterns of coronary heart disease mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383–90.
   PubMed Web of Science ®Google Scholar
• Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age and sex. Am Heart J 2003; 145(5): 888–95.
   PubMed Web of Science ®Google Scholar
• Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 1421–6.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for 1 million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Cohen BA, Wingard DL, Edelstein DL. Why is diabetes mellitus a stronger risk factor for ischemic heart disease in women than in men? The Rancho Bernado study. JAMA 1991; 265: 627–31.
   PubMed Web of Science ®Google Scholar
• Hu G, Jousilahti P, Qiao Q, et al. Sex differences in cardiovascular and total mortality among diabetic and non diabetic individuals with or without history of myocardial infarction. Diabetologica 2005; 48(5): 856–61.
   PubMed Web of Science ®Google Scholar
• Steiidell JC, Verschuren WM, van LeerEM, Kromhout D. Overweight, underweight, and mortality. A prospective study of 48,287 men and women. Arch Intern Med 1996; 156990: 958–63.
   Google Scholar
• Murphy NF, MacIntyre K, Stewart S, et al. Longterm cardiovascular consequences of obesity: a 20 year follow-up of more than 15,000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006: 27(1)96–106.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman MD, Daniels SR et al. Diagnosis and Management of Metabolic Syndrome. An American Heart Association/National Heart Lung, and Blood Institute Scientific Statement. Circulation published online Sep 12 2005. Available at www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Downloaded 17 December 2006.
   Google Scholar
• Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National health and nutrition Examination Survey, 1988–1994. Arch Intern Med 2003; 163: 427–36.
   Google Scholar
• Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104–9.
   PubMed Web of Science ®Google Scholar
• Diverse Populations Collaboration. Smoking, body weight, and CHD mortality in diverse populations. Prev Med 2004; 38: 834–40.
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Post-menopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208.
   PubMed Web of Science ®Google Scholar
• Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentrations. PEPI investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998; 97: 979–86.
   PubMed Web of Science ®Google Scholar
• Lakoski SG and Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric. 2005; 8: 317–326.
   PubMed Web of Science ®Google Scholar
• Lewandowski KC, Komorowski J, Mikhalides DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metal-loproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006; 91(8): 3123–30.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Laughlin GA. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernado Study. Menopause 2005; 12(1): 40–48.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study. JAMA 1998; 280: 605–13.
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin replacement Study follow-up [HERS II}. JAMA 2002; 288(1): 49–57.
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343(8): 522–90.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med. 2003; 349(6): 535–45.
   PubMed Web of Science ®Google Scholar
• Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002; 109(9): 1056–62.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Study Group. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of Coronary Heart Disease. N Engl J Med 2003; 349(6): 523–534.
   PubMed Web of Science ®Google Scholar
• Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006; 13(1): 139–47.
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al. Conjugated Equine Estrogens and coronary Heart Disease. Arch Intern Med 2006: 166; 351–61.
   Google Scholar
• Grodstein F, Manson JE, Stampfer MJ, et al. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Womens Health (Larchmt) 2006; 15(1): 35–44.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605–619.
   PubMed Web of Science ®Google Scholar
• Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Prevention Study. Climacteric 2005; 8: 3–12.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascuar disease in women. N Engl J Med 2005; 352(13): 1293–304.
   PubMed Web of Science ®Google Scholar
• Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291: 2243–52.
   PubMed Web of Science ®Google Scholar
• Mosca L, Appel LJ, Benjamin EL, et al. Evidence based guidelines for cardiovascular disease prevention in women. Arterioscl Thromb Vasc Biol 2004; 24(3): e24–50.
   Web of Science ®Google Scholar